Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer
The Pharma Data
JANUARY 4, 2021
Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients’ disease worsened. .
Let's personalize your content